New Cancer Cure-Bio Co.,Ltd.
🇰🇷South Korea
Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of KN510, KN713
Phase 1
Completed
- Conditions
- Advanced Solid Tumors
- Interventions
- Drug: KN510 120mg/day + KN713 120mg/dayDrug: KN510 60mg/day + KN713 60mg/dayDrug: KN510 120mg/day + KN713 60mg/dayDrug: KN510 120mg/day + KN713 90mg/day
- First Posted Date
- 2023-08-25
- Last Posted Date
- 2025-01-08
- Lead Sponsor
- New Cancer Cure-Bio Co.,Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT06012708
- Locations
- 🇰🇷
National Cancer Center, Goyang-si, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath